UCB, Weill Cornell Medical College deal

UCB partnered with the medical college to advance the college's translational research programs in bone disorders, metabolic disease and rare genetic variant analysis. UCB, which will perform antibody generation and medicinal chemistry, will provide about $8 million in research funding to the college during the three-year deal. In return, UCB received an exclusive right to negotiate an exclusive license to develop and commercialize resulting products. UCB said there will be an academic lead from Cornell and a project lead from UCB for each project. ...